Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
Get guidance on the practical use of rivaroxaban for the treatment of patients with VTE. British Journal of Cardiology
Event rates were low, but no major bleeding complications and no thromboembolic events occurred in the ablation group that had rivaroxaban maintained during the AF procedure. Heartwire from Meds...
More findings show similar safety and efficacy rates between the two treatments, whether or not AF patients also have diabetes, suggesting rivaroxaban may be a feasible alternative. Heartwire fr...
HemosIL, a solution developed by Instrumentation Laboratory to test for rivaroxaban, has obtained CE mark approval from Europ -More-
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.Design...
Read more about Trial Explores Rivaroxaban in Catheter AblationComments
Janssen Pharmaceuticals and its development partner, Bayer HealthCare, have initiated CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patie...
In final guidance from the National Institute for Health and Care Excellence (NICE), it recommends Xarelto (rivaroxaban; Bayer) in combination with clopidogrel and aspirin, or with aspirin alone, as a...
Although colchicine has been a focus of research, debate and controversy for thousands of years, it was only approved by the United States Food and Drug Administration in 2009. Over the past decade, a...
The prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing ...
Rivaroxaban is a factor-Xa-inhibitor which has been shown to be non-inferior to the vitamin-K-antagonist (VKA) warfarin in atrial fibrillation patients. In the manufacturer-sponsored trial, the rate o...
Rivaroxaban is increasingly used to treat patients with acute venous thromboembolism (VTE), a potentially life-threatening condition. Since absorption of rivaroxaban decreases from nearly 100% to 66% ...
Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation. We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage.